AstraZeneca PLC Files Form 6-K for August 2025

TL;DR

AZN filed a routine 6-K for August 2025, no major news.

AI Summary

AstraZeneca PLC filed a Form 6-K on August 1, 2025, reporting for the month of August 2025. The company, previously known as ZENECA GROUP PLC until April 22, 1993, is a foreign issuer based in Cambridge, United Kingdom, and is required to file under the 1934 Act.

Why It Matters

This filing indicates ongoing reporting requirements for AstraZeneca PLC, a major pharmaceutical company, to the SEC.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign issuer and does not contain specific financial or operational updates that would typically indicate significant risk.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the Form 6-K
• ZENECA GROUP PLC (company) — Former name of AstraZeneca PLC
• 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (company) — Business and mail address of AstraZeneca PLC
• 001-11960 (company) — SEC file number for AstraZeneca PLC
• 19930422 (date) — Date of name change from ZENECA GROUP PLC
• 20250801 (date) — Filing date and period of report

FAQ

From the Filing

0001654954-25-008838.txt : 20250801 0001654954-25-008838.hdr.sgml : 20250801 20250801143219 ACCESSION NUMBER: 0001654954-25-008838 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250801 FILED AS OF DATE: 20250801 DATE AS OF CHANGE: 20250801 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251175618 BUSINESS ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a6194t.htm TOTAL VOTING RIGHTS a6194t FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of August 2025    Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________     AstraZeneca PLC   INDEX TO EXHIBITS     1. Total Voting Rights   1 August 2025 Transparency Directive   Voting rights and capital   The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 July 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,682,580 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,682,580.   The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.   AstraZeneca   AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit  astrazeneca.com  and follow the Company on social media  @AstraZeneca       Contacts For details on how to contact the Investor Relations Team, please click  here . For Media contacts, click  here .   Matthew Bowden   Company Secretary   AstraZeneca PLC     SIGNATURES &#x